In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against Acute Myeloid Leukemia
Infiltration of tumors by EBV-CTLs. Forty-eight hours after i.v. administration of EBV-CTLs, tumors were resected, fixed in 10% formalin solution, and embedded in paraffin. CD8+ EBV-CTLs were detected by immunohistochemistry using an anti-CD8 antibody and reported in (a) unmodified EBV-CTLs, (b) CD33-EBV-CTLs. Genetically modified T cells were found at the periphery of the tumor in the vicinity of vessels (indicated as “V”), isolated or forming cluster (arrowheads or arrows, resp.).
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.